Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Mannkind Corp (NQ: MNKD )

6.900 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 6.900
Bid (Size) 6.900 (2)
Ask (Size) 7.230 (1)
Prev. Close 6.900
Today's Range 6.900 - 6.900
52wk Range 3.170 - 7.630
Shares Outstanding 264,305,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MannKind (MNKD) Q3 2024 Earnings Call Transcript
MNKD earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire

Performance

YTD
+76.02%
+76.02%
1 Month
+3.92%
+3.92%
3 Month
+29.46%
+29.46%
6 Month
+43.15%
+43.15%
1 Year
+89.04%
+89.04%

More News

Read More
MannKind to Present at 2024 UBS Healthcare Conference
From MannKind
Via GlobeNewswire
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
From MannKind
Via GlobeNewswire
Lytham Partners Announces KOL Panels and Participating Companies for its Fall 2024 Investor Conference
Via Newsfile
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
From MannKind
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
From MannKind
Via GlobeNewswire
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
MannKind to Present at Upcoming Conferences
From MannKind
Via GlobeNewswire
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
From MannKind
Via GlobeNewswire
MannKind (MNKD) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
From MannKind
Via GlobeNewswire
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
From MannKind
Via GlobeNewswire
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker
Via The Motley Fool
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
From MannKind
Via GlobeNewswire
MannKind (MNKD) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
MNKD Stock Earnings: MannKind Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
From MannKind
Via GlobeNewswire
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.